Pharmaceutical News

RSS

Researchers develop single vaccines to prevent rabies, Ebola infection

Researchers from Thomas Jefferson University, among other institutions, including the National Institute of Allergy and Infectious Diseases, have developed single vaccines to protect against both rabies and the Ebola virus.

26 Aug 2011

IOM issues new report on evidence and causality of vaccine harms

The Institute of Medicine's Panel on Adverse Effects of Vaccines issued a report today on the evidence and causality of vaccine harms. Despite a glowing press release, the report does little to allay public concerns over adverse effects of vaccines and suggests that we urgently need more science on vaccine adverse effects.

26 Aug 2011

Firazyr receives FDA approval for treatment of HAE acute attacks

The U.S. Food and Drug Administration today approved Firazyr (icatibant) Injection for the treatment of acute attacks of a rare condition called hereditary angioedema (HAE) in people ages 18 years and older.

26 Aug 2011

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Boehringer Ingelheim and Eli Lilly and Company today received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets for the treatment of adults with type 2 diabetes.

26 Aug 2011

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

Shire plc, the global specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for FIRAZYR for treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

26 Aug 2011

Antidepressant alert – Citalopram associated to heart rhythm disturbances

Antidepressant citalopram (Celexa, Forest Laboratories) should not be used in doses higher than 40 mg per day because of concerns that it can cause potentially fatal changes in heart rhythm, the US Food and Drug Administration (FDA) warns.

25 Aug 2011

Allergan gets FDA nod for use of Botox in urinary incontinence

Allergan Inc. has received United States Food and Drug Administration (FDA) approval to market the wrinkle smoother Botox as a treatment for urinary incontinence. The FDA approved the drug for people with overactive bladders who have neurologic conditions such as multiple sclerosis and spinal cord injuries, the agency said today in a statement. The medicine is injected into the bladder to increase its capacity by relaxing muscles.

25 Aug 2011

Simcere receives Chinese SFDA approval for Iremod to treat active rheumatoid arthritis

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that it has received the new drug approval from the State Food and Drug Administration for Iremod.

25 Aug 2011

Removal of OTC drugs for toddlers from the market reduces therapeutic errors

A new study by researchers at the University of Maryland has revealed a 46 percent drop in reported errors after drugmakers in October 2007 removed from the market a number of over-the-counter cough and cold medications labeled for children under the age of 2.

25 Aug 2011

AHF shares The Lancet's concerns over use of Gilead's Truvada as HIV prevention pill

Today AIDS Healthcare Foundation (AHF) commented on an editorial published in the September 2011 issue of The Lancet Infectious Diseases that raises concerns about the use of the HIV treatment drug Truvada, manufactured by Gilead Sciences Inc., as an HIV prevention pill or pre-exposure prophylaxis (PrEP), agreeing with the publication's public health concerns.

25 Aug 2011

Redesigned vancomycin can kill deadliest antibiotic-resistant bacteria

A team of scientists from The Scripps Research Institute have successfully reengineered an important antibiotic to kill the deadliest antibiotic-resistant bacteria.

25 Aug 2011

Webinar on Prescription Drug Abuse in Workers' Comp

Joseph Paduda, principal of Health Strategy Associates, will present "Prescription Drug Abuse in Workers' Comp," an hour-long webinar on Thursday, Sept. 1, starting 1 p.m. (PDT)/ 4 p.m. EDT.

25 Aug 2011

Foreign drug manufacturing, testing raise regulatory and ethical concerns

JAMA discusses "a recent report from the Pew Health Group about the growing risks of substandard and counterfeit medications resulting from the increasing overseas production of pharmaceuticals and their ingredients."

25 Aug 2011

Researchers discover how antipsychotic drugs manage symptoms of schizophrenia

The classic symptoms of schizophrenia - paranoia, hallucinations, the inability to function socially-can be managed with antipsychotic drugs. But exactly how these drugs work has long been a mystery.

25 Aug 2011

Allergan receives FDA approval for Botox to treat specific form of urinary incontinence

The U.S. Food and Drug Administration today approved Botox injection to treat urinary incontinence in people with neurologic conditions such as spinal cord injury and multiple sclerosis who have overactivity of the bladder.

25 Aug 2011

NMS Labs develops substance identification tests for nine 'bath salts' compounds

In keeping up with drug abuse trends, NMS Labs has developed substance identification tests for the nine "bath salts" compounds listed in the recently approved PA Senate Bill 1006.

25 Aug 2011

USPTO issues Notice of Allowance for Cortex AMPAKINE molecules to treat respiratory depression

Cortex Pharmaceuticals, Inc. announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent that protects the use of AMPAKINE molecules for the treatment or prevention of respiratory depression.

25 Aug 2011

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX for injection for the treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition in adults who have an inadequate response to or are intolerant of an anticholinergic medication.

25 Aug 2011

Mylan subsidiary to exclusively offer EpiPen 2-Pak and EpiPen Jr 2-Pak Auto-Injector

Dey Pharma, L.P., a subsidiary of Mylan Inc., today announced that Dey will exclusively offer the EpiPen 2-Pak and EpiPen Jr 2-Pak (epinephrine) Auto-Injector 0.3/0.15 mg, to encourage physicians and patients to follow recommendations by the National Institute of Allergy and Infectious Diseases (NIAID).

24 Aug 2011

A pain-free way of tackling dental decay

Researchers at the University of Leeds have discovered a pain-free way of tackling dental decay that reverses the damage of acid attack and re-builds teeth as new.

24 Aug 2011

Pharmaceutical News

Researchers develop single vaccines to prevent rabies, Ebola infection

IOM issues new report on evidence and causality of vaccine harms

Firazyr receives FDA approval for treatment of HAE acute attacks

Boehringer Ingelheim, Lilly receive EU approval for linagliptin to treat type 2 diabetes

Shire receives FDA marketing approval for FIRAZYR to treat acute attacks of HAE

Antidepressant alert – Citalopram associated to heart rhythm disturbances

Allergan gets FDA nod for use of Botox in urinary incontinence

Simcere receives Chinese SFDA approval for Iremod to treat active rheumatoid arthritis

Removal of OTC drugs for toddlers from the market reduces therapeutic errors

AHF shares The Lancet's concerns over use of Gilead's Truvada as HIV prevention pill

Redesigned vancomycin can kill deadliest antibiotic-resistant bacteria

Webinar on Prescription Drug Abuse in Workers' Comp

Foreign drug manufacturing, testing raise regulatory and ethical concerns

Researchers discover how antipsychotic drugs manage symptoms of schizophrenia

Allergan receives FDA approval for Botox to treat specific form of urinary incontinence

NMS Labs develops substance identification tests for nine 'bath salts' compounds

USPTO issues Notice of Allowance for Cortex AMPAKINE molecules to treat respiratory depression

FDA approves Allergan's BOTOX to treat specific form of urinary incontinence

Mylan subsidiary to exclusively offer EpiPen 2-Pak and EpiPen Jr 2-Pak Auto-Injector

A pain-free way of tackling dental decay

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News